-+ 0.00%
-+ 0.00%
-+ 0.00%

Outlook Therapeutics launches public offering with accompanying stock purchase warrants

PUBT·08/12/2026 20:01:56
Listen to the news
Outlook Therapeutics launches public offering with accompanying stock purchase warrants
  • Outlook Therapeutics launched an underwritten public offering of common stock with accompanying warrants to buy common shares.
  • Underwriters received a 30-day option to purchase up to 15% more shares and/or accompanying warrants on the same terms.
  • Net proceeds earmarked for the US commercial launch of LYTENAVA, working capital, general corporate purposes.
  • Offering made under an effective shelf registration statement on Form S-3 filed March 28, 2024; effective April 5, 2024.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608121601PRIMZONEFULLFEED9808997) on August 12, 2026, and is solely responsible for the information contained therein.